GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 36 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,436 | -47.7% | 846 | -30.8% | 0.00% | – |
| Q2 2023 | $4,660 | +229.6% | 1,223 | +60.9% | 0.00% | – |
| Q1 2023 | $1,414 | -20.2% | 760 | -1.4% | 0.00% | – |
| Q4 2022 | $1,773 | -11.4% | 771 | +7.4% | 0.00% | – |
| Q3 2022 | $2,000 | -88.2% | 718 | -76.8% | 0.00% | – |
| Q2 2022 | $17,000 | +112.5% | 3,089 | -10.6% | 0.00% | – |
| Q1 2022 | $8,000 | -79.5% | 3,455 | -46.6% | 0.00% | – |
| Q4 2021 | $39,000 | +178.6% | 6,474 | +562.0% | 0.00% | – |
| Q3 2021 | $14,000 | -51.7% | 978 | -56.2% | 0.00% | – |
| Q2 2021 | $29,000 | +93.3% | 2,232 | +123.2% | 0.00% | – |
| Q1 2021 | $15,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 3,445,973 | $8,029,000 | 0.68% |
| Paradigm Biocapital Advisors LP | 783,445 | $1,825,000 | 0.48% |
| Orbimed Advisors | 7,884,870 | $18,372,000 | 0.30% |
| Vivo Capital, LLC | 961,359 | $2,240,000 | 0.15% |
| EcoR1 Capital, LLC | 1,559,710 | $3,634,000 | 0.11% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $23,071,520 | 0.10% |
| Capital International, Inc./CA/ | 2,335,476 | $5,442,000 | 0.06% |
| Virtus ETF Advisers LLC | 24,728 | $58,000 | 0.03% |
| Capital International Sarl | 228,149 | $532,000 | 0.03% |
| FEDERATED HERMES, INC. | 1,298,578 | $3,026,000 | 0.01% |